ArticleInvestigational new drugs2016

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.

Kiyotaka Yoh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.